![Frances Wildhaber](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
PD Dr. Wildhaber joined BioMedPartners in January 2007.
Previously, she was a Managing Director for the Novartis Venture Fund where she served on the boards of Athelas, NanoPowers, CellnTec and Oncalis.
She has more than 19 years of experience in pharmaceutical R&D and business development.
In Novartis, she was Head of Immunology Project Management, Immunology Research, Oncology Business Development and Licensing as well as a member of the Corporate Mergers and Acquisition team.
Prior to joining Novartis, Dr. Wildhaber performed postdoctoral research on tumor virology (FMI-Basel), membrane proteins and lipids (ETH-Zurich) and monoclonal antibodies and crystallisation of bacterial photosynthetic proteins (MPI-Munich).
Her qualifications include a Biochemistry B.Sc.
(UK), Ph.D (performed at Max Planck Institute for Immunology, Freiburg) and PD (Privatdozentin) from the ETH-Zurich.
Anciens postes connus de Frances Wildhaber
| Sociétés | Poste | Fin |
|---|---|---|
BioMedPartners AG
 BioMedPartners AG Investment ManagersFinance BioMedPartners invests in companies located in Switzerland, Germany and neighboring Western Europe. The firm focuses on biotechnology, emerging pharmaceutical, medical technology and other healthcare-related industries such as diagnostics or platform technologies. It participates in seed and early stage capital transactions. It also makes follow-on investments and acts a lead or co-lead investor. | Private Equity Investor | 01/03/2009 |
Novartis Venture Funds
 Novartis Venture Funds Investment ManagersFinance NVF invests in companies located across North America and Europe. The firm focuses on biotechnology & biopharmaceutical and Life science sectors. It provides financing for early and later stage transactions with an investment size up to USD 30 million per company and also acts as lead or co-lead investor. The firm takes a seat on the board of directors. | Directeur en chef des Investissements | 01/01/2007 |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
2
Relations au 1er degré
2
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Novartis Venture Funds
Novartis Venture Funds Investment ManagersFinance NVF invests in companies located across North America and Europe. The firm focuses on biotechnology & biopharmaceutical and Life science sectors. It provides financing for early and later stage transactions with an investment size up to USD 30 million per company and also acts as lead or co-lead investor. The firm takes a seat on the board of directors. | Finance |
BioMedPartners AG
BioMedPartners AG Investment ManagersFinance BioMedPartners invests in companies located in Switzerland, Germany and neighboring Western Europe. The firm focuses on biotechnology, emerging pharmaceutical, medical technology and other healthcare-related industries such as diagnostics or platform technologies. It participates in seed and early stage capital transactions. It also makes follow-on investments and acts a lead or co-lead investor. | Finance |
